REFERENCES
1. Pathak RK, Sanders P, Deo R. Primary prevention implantable
cardioverter-defibrillator and opportunities for sudden cardiac death
risk assessment in non-ischaemic cardiomyopathy. Eur Heart J
2018;39:2859-2866.
2. Poole JE, Olshansky B, Mark DB et al. Long-Term Outcomes of
Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. J Am
Coll Cardiol 2020;76:405-415.
3. Bart BA, Shaw LK, McCants CB et al. Clinical Determinants of
Mortality in Patients With Angiographically Diagnosed Ischemic or
Nonischemic Cardiomyopathy. Journal of the American College of
Cardiology 1997;30:1002-1008.
4. Felker GM, Shaw LK, O’Connor CM. A standardized definition of
ischemic cardiomyopathy for use in clinical research. Journal of the
American College of Cardiology 2002;39:210-218.
5. Majmudar MD, Murthy VL, Shah RV et al. Quantification of coronary
flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy
and its association with clinical outcomes. Eur Heart J Cardiovasc
Imaging 2015;16:900-9.
6. Frankenstein L, Hees H, Taeger T et al. Clinical characteristics,
morbidity, and prognostic value of concomitant coronary artery disease
in idiopathic dilated cardiomyopathy. Clin Res Cardiol 2013;102:771-80.
7. Canu M, Margerit L, Mekhdoul I et al. Prognosis of Coronary
Atherosclerotic Burden in Non-Ischemic Dilated Cardiomyopathies. J Clin
Med 2021;10.
8. Braga JR, Austin PC, Ross HJ, Tu JV, Lee DS. Importance of
Nonobstructive Coronary Artery Disease in the Prognosis of Patients With
Heart Failure. JACC Heart Fail 2019;7:493-501.
9. Bennett RG, Campbell T, Kotake Y, Turnbull S, Kumar S. Clinical,
Electroanatomic and Electrophysiologic Characterization, and Outcomes of
Catheter Ablation for Ventricular Tachycardia in Patients With a Mixed
Cardiomyopathy. Circ Arrhythm Electrophysiol 2022:CIRCEP121010476.
10. Madias JE. Ischemic, nonischemic, and probably ”mixed” dilated
cardiomyopathies: what’s in a definition? Int J Cardiol 2014;175:565-6.
11. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an Implantable
Cardioverter–Defibrillator for Congestive Heart Failure. New England
Journal of Medicine 2005;352:225-237.
12. Repetto A, Dal Bello B, Pasotti M et al. Coronary atherosclerosis in
end-stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur
Heart J 2005;26:1519-27.
13. Albakri A. Ischemic cardiomyopathy: A review of literature on
clinical status and meta-analysis of diagnostic and clinical management.
Biology, Engineering and Medicine 2018;3.
14. Das D, Asher A, Ghosh AK. Cancer and Coronary Artery Disease: Common
Associations, Diagnosis and Management Challenges. Curr Treat Options
Oncol 2019;20:46.
15. Goodwill AG, Dick GM, Kiel AM, Tune JD. Regulation of Coronary Blood
Flow. Compr Physiol 2017;7:321-382.
16. Yong AS, Ho M, Shah MG, Ng MK, Fearon WF. Coronary microcirculatory
resistance is independent of epicardial stenosis. Circ Cardiovasc Interv
2012;5:103-8, S1-2.
17. Paterson I, Mielniczuk LM, O’Meara E, So A, White JA. Imaging heart
failure: current and future applications. Can J Cardiol 2013;29:317-28.
18. Aldhoon B, Tzou WS, Riley MP et al. Nonischemic cardiomyopathy
substrate and ventricular tachycardia in the setting of coronary artery
disease. Heart Rhythm 2013;10:1622-7.
19. Hutchinson MD, Gerstenfeld EP, Desjardins B et al. Endocardial
unipolar voltage mapping to detect epicardial ventricular tachycardia
substrate in patients with nonischemic left ventricular cardiomyopathy.
Circ Arrhythm Electrophysiol 2011;4:49-55.
20. Gulsin GS, Shetye A, Khoo J et al. Does stress perfusion imaging
improve the diagnostic accuracy of late gadolinium enhanced cardiac
magnetic resonance for establishing the etiology of heart failure? BMC
Cardiovasc Disord 2017;17:98.